Skip to main content
. 2020 May 30;25(8):e1188–e1194. doi: 10.1634/theoncologist.2020-0161

Figure 2.

Figure 2

Guradant360 ctDNA assay of patients treated with regorafenib and PD‐1 inhibitor. (A, B): ctDNA of SD patients. (C, D): ctDNA of PD patients. (E): The highest MAF change at baseline and 4 weeks after treatment in patients with PD. (F): The highest MAF change at baseline and 4 weeks after treatment in patients with SD.

Abbreviations: MAF, mutation allele frequency; PD, progressive disease; SD, stable disease.